Hodgkin Lymphoma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：207頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Hodgkin Lymphoma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Hodgkin Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Hodgkin Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Hodgkin Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Hodgkin Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Hodgkin Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for Hodgkin Lymphoma - Overview 11
Pipeline Products for Hodgkin Lymphoma - Comparative Analysis 12
Hodgkin Lymphoma - Therapeutics under Development by Companies 13
Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 16
Hodgkin Lymphoma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Hodgkin Lymphoma - Products under Development by Companies 22
Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 23
Hodgkin Lymphoma - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
Seattle Genetics, Inc. 25
Gilead Sciences, Inc. 26
Merck & Co., Inc. 27
Gamida Cell Ltd. 28
Plexxikon Inc. 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
Ono Pharmaceutical Co., Ltd. 32
Cell Therapeutics, Inc. 33
Incyte Corporation 34
4SC AG 35
Dynavax Technologies Corporation 36
Spectrum Pharmaceuticals, Inc. 37
Affimed Therapeutics AG 38
Actinium Pharmaceuticals, Inc. 39
Philogen S.p.A. 40
MABLife S.A.S 41
Stemline Therapeutics, Inc. 42
Syndax Pharmaceuticals, Inc. 43
Janssen Research & Development, LLC 44
Sigma-Tau Pharmaceuticals, Inc 45
Rhizen Pharmaceuticals SA 46
Immune Pharmaceuticals, Inc. 47
Pharmedartis GmbH 48
Hodgkin Lymphoma - Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Target 50
Assessment by Mechanism of Action 54
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
procarbazine hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
panobinostat - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
StemEx - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
brentuximab vedotin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
entinostat - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pacritinib - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
mocetinostat - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
resminostat - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
idelalisib - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
pralatrexate - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
PLX-3397 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
radretumab - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Iomab-B - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Ferritarg - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
JNJ-40346527 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Minor Histocompatibility Antigen - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
pevonedistat hydrochloride - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
brentuximab vedotin - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
MDX-1401 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
vinorelbine tartrate liposomal - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
SD-101 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
AFM-13 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
ciclopirox olamine - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
EBV-Specific T-Lymphocytes - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
NSC-678515 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
nivolumab - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Autologous CAR.CD30 EBV Specific Cytotoxic T Lymphocytes - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
lambrolizumab - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Genetically Modified T Cell - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
INCB-047986 - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
LMP-Specific Cytotoxic T Cells - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
SL-101 - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
TGR-1202 - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Human Granzyme B Based Immunotoxin - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
Ferritizumab - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Hodgkin Lymphoma - Recent Pipeline Updates 139
Hodgkin Lymphoma - Dormant Projects 189
Hodgkin Lymphoma - Discontinued Products 190
Hodgkin Lymphoma - Product Development Milestones 191
Featured News & Press Releases 191
Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma 191
Dec 05, 2013: TG Therapeutics Announces Poster Presentations for TGR-1202 at the Upcoming 55th American Society of Hematology Meeting 191
Oct 11, 2013: Seattle Genetics Highlights ADCETRIS (Brentuximab Vedotin) Clinical Data in the Frontline Setting at the International Symposium on Hodgkin Lymphoma 192
Sep 16, 2013: Affimed Therapeutics and The Leukemia & Lymphoma Society Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Patients 195
Jun 24, 2013: Affimed Reports Phase I Clinical Data For Its Immunotherapy AFM13 In Relapsing/Refractory Hodgkin Lymphoma Patients 195
Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML 197
Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma 199
Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma 201
Jun 10, 2013: Seattle Genetics Initiates Phase I/II Trial Of Adcetris In Combination With Bendamustine For Hodgkin Lymphoma Patients After Initial Relapse 203
Jun 02, 2013: Seattle Genetics Announces Presentation Of Adcetris Clinical Development Programs At ASCO Annual Meeting 2013 204
Appendix 206
Methodology 206
Coverage 206
Secondary Research 206
Primary Research 206
Expert Panel Validation 206
Contact Us 207
Disclaimer 207
List of Tables
Number of Products under Development for Hodgkin Lymphoma, H1 2014 11
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Development, H1 2014 20
Comparative Analysis by Unknown Stage Development, H1 2014 21
Products under Development by Companies, H1 2014 22
Products under Investigation by Universities/Institutes, H1 2014 23
Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 24
Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2014 25
Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014 26
Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 27
Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2014 28
Hodgkin Lymphoma - Pipeline by Plexxikon Inc., H1 2014 29
Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 30
Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2014 31
Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 32
Hodgkin Lymphoma - Pipeline by Cell Therapeutics, Inc., H1 2014 33
Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2014 34
Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2014 35
Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2014 36
Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 37
Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2014 38
Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 39
Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2014 40
Hodgkin Lymphoma - Pipeline by MABLife S.A.S, H1 2014 41
Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2014 42
Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2014 43
Hodgkin Lymphoma - Pipeline by Janssen Research & Development, LLC., H1 2014 44
Hodgkin Lymphoma - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2014 45
Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 46
Hodgkin Lymphoma - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 47
Hodgkin Lymphoma - Pipeline by Pharmedartis GmbH, H1 2014 48
Assessment by Monotherapy Products, H1 2014 49
Number of Products by Stage and Target, H1 2014 52
Number of Products by Stage and Mechanism of Action, H1 2014 56
Number of Products by Stage and Route of Administration, H1 2014 60
Number of Products by Stage and Molecule Type, H1 2014 62
Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 139
Hodgkin Lymphoma - Dormant Projects, H1 2014 189
Hodgkin Lymphoma - Discontinued Products, H1 2014 190
List of Figures
Number of Products under Development for Hodgkin Lymphoma, H1 2014 11
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Products, H1 2014 20
Assessment by Monotherapy Products, H1 2014 49
Number of Products by Top 10 Target, H1 2014 50
Number of Products by Stage and Top 10 Target, H1 2014 51
Number of Products by Top 10 Mechanism of Action, H1 2014 54
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 55
Number of Products by Top 10 Route of Administration, H1 2014 59
Number of Products by Stage and Top 10 Route of Administration, H1 2014 60
Number of Products by Top 10 Molecule Type, H1 2014 61
Number of Products by Stage and Top 10 Molecule Type, H1 2014 62
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Hodgkin Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for Hodgkin Lymphoma - Overview 11
Pipeline Products for Hodgkin Lymphoma - Comparative Analysis 12
Hodgkin Lymphoma - Therapeutics under Development by Companies 13
Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 16
Hodgkin Lymphoma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Hodgkin Lymphoma - Products under Development by Companies 22
Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 23
Hodgkin Lymphoma - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
Seattle Genetics, Inc. 25
Gilead Sciences, Inc. 26
Merck & Co., Inc. 27
Gamida Cell Ltd. 28
Plexxikon Inc. 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
Ono Pharmaceutical Co., Ltd. 32
Cell Therapeutics, Inc. 33
Incyte Corporation 34
4SC AG 35
Dynavax Technologies Corporation 36
Spectrum Pharmaceuticals, Inc. 37
Affimed Therapeutics AG 38
Actinium Pharmaceuticals, Inc. 39
Philogen S.p.A. 40
MABLife S.A.S 41
Stemline Therapeutics, Inc. 42
Syndax Pharmaceuticals, Inc. 43
Janssen Research & Development, LLC 44
Sigma-Tau Pharmaceuticals, Inc 45
Rhizen Pharmaceuticals SA 46
Immune Pharmaceuticals, Inc. 47
Pharmedartis GmbH 48
Hodgkin Lymphoma - Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Target 50
Assessment by Mechanism of Action 54
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
procarbazine hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
panobinostat - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
StemEx - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
brentuximab vedotin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
entinostat - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pacritinib - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
mocetinostat - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
resminostat - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
idelalisib - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
pralatrexate - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
PLX-3397 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
radretumab - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Iomab-B - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Ferritarg - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
JNJ-40346527 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Minor Histocompatibility Antigen - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
pevonedistat hydrochloride - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
brentuximab vedotin - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
MDX-1401 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
vinorelbine tartrate liposomal - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
SD-101 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
AFM-13 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
ciclopirox olamine - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
EBV-Specific T-Lymphocytes - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
NSC-678515 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
nivolumab - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Autologous CAR.CD30 EBV Specific Cytotoxic T Lymphocytes - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
lambrolizumab - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Genetically Modified T Cell - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
INCB-047986 - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
LMP-Specific Cytotoxic T Cells - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
SL-101 - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
TGR-1202 - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Human Granzyme B Based Immunotoxin - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
Ferritizumab - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Hodgkin Lymphoma - Recent Pipeline Updates 139
Hodgkin Lymphoma - Dormant Projects 189
Hodgkin Lymphoma - Discontinued Products 190
Hodgkin Lymphoma - Product Development Milestones 191
Featured News & Press Releases 191
Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma 191
Dec 05, 2013: TG Therapeutics Announces Poster Presentations for TGR-1202 at the Upcoming 55th American Society of Hematology Meeting 191
Oct 11, 2013: Seattle Genetics Highlights ADCETRIS (Brentuximab Vedotin) Clinical Data in the Frontline Setting at the International Symposium on Hodgkin Lymphoma 192
Sep 16, 2013: Affimed Therapeutics and The Leukemia & Lymphoma Society Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Patients 195
Jun 24, 2013: Affimed Reports Phase I Clinical Data For Its Immunotherapy AFM13 In Relapsing/Refractory Hodgkin Lymphoma Patients 195
Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML 197
Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma 199
Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma 201
Jun 10, 2013: Seattle Genetics Initiates Phase I/II Trial Of Adcetris In Combination With Bendamustine For Hodgkin Lymphoma Patients After Initial Relapse 203
Jun 02, 2013: Seattle Genetics Announces Presentation Of Adcetris Clinical Development Programs At ASCO Annual Meeting 2013 204
Appendix 206
Methodology 206
Coverage 206
Secondary Research 206
Primary Research 206
Expert Panel Validation 206
Contact Us 207
Disclaimer 207
List of Tables
Number of Products under Development for Hodgkin Lymphoma, H1 2014 11
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Development, H1 2014 20
Comparative Analysis by Unknown Stage Development, H1 2014 21
Products under Development by Companies, H1 2014 22
Products under Investigation by Universities/Institutes, H1 2014 23
Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 24
Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2014 25
Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014 26
Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 27
Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2014 28
Hodgkin Lymphoma - Pipeline by Plexxikon Inc., H1 2014 29
Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 30
Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2014 31
Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 32
Hodgkin Lymphoma - Pipeline by Cell Therapeutics, Inc., H1 2014 33
Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2014 34
Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2014 35
Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2014 36
Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 37
Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2014 38
Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 39
Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2014 40
Hodgkin Lymphoma - Pipeline by MABLife S.A.S, H1 2014 41
Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2014 42
Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2014 43
Hodgkin Lymphoma - Pipeline by Janssen Research & Development, LLC., H1 2014 44
Hodgkin Lymphoma - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2014 45
Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 46
Hodgkin Lymphoma - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 47
Hodgkin Lymphoma - Pipeline by Pharmedartis GmbH, H1 2014 48
Assessment by Monotherapy Products, H1 2014 49
Number of Products by Stage and Target, H1 2014 52
Number of Products by Stage and Mechanism of Action, H1 2014 56
Number of Products by Stage and Route of Administration, H1 2014 60
Number of Products by Stage and Molecule Type, H1 2014 62
Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 139
Hodgkin Lymphoma - Dormant Projects, H1 2014 189
Hodgkin Lymphoma - Discontinued Products, H1 2014 190
List of Figures
Number of Products under Development for Hodgkin Lymphoma, H1 2014 11
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Products, H1 2014 20
Assessment by Monotherapy Products, H1 2014 49
Number of Products by Top 10 Target, H1 2014 50
Number of Products by Stage and Top 10 Target, H1 2014 51
Number of Products by Top 10 Mechanism of Action, H1 2014 54
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 55
Number of Products by Top 10 Route of Administration, H1 2014 59
Number of Products by Stage and Top 10 Route of Administration, H1 2014 60
Number of Products by Top 10 Molecule Type, H1 2014 61
Number of Products by Stage and Top 10 Molecule Type, H1 2014 62
